Fenretinide Treatment Prevents Diet-Induced Obesity in Association With Major Alterations in Retinoid Homeostatic Gene Expression in Adipose, Liver, and Hypothalamus

George D. McIlroy, Mirela Delibegovic, Carl Owen, Patrick N. Stoney, Kirsty D. Shearer, Peter J. McCaffery, and Nimesh Mody

The original retinoid, Fenretinide (FEN), inhibits obesity and insulin resistance in mice and is in early clinical trials for treatment of insulin resistance in obese humans. We aimed to determine whether alterations in retinoic acid (RA)-responsive genes contribute to the beneficial effects of FEN. We examined the effect of FEN on 3T3-L1 adipocyte differentiation and alterations in gene expression in C57Bl/6 and retinaldehyde dehydrogenase (RALDH1) KO mice. In mice fed an HF diet, RA-responsive genes were markedly increased in adipose, liver, and hypothalamus, with short-term and long-term FEN treatment. In adipose, FEN inhibited the downregulation of PPARγ and improved insulin sensitivity and the levels of adiponectin, resistin, and serum RBP (RBP4). FEN inhibited hyperleptinemia in vivo and leptin expression in adipocytes. Surprisingly, hypothalamic neuropeptide Y expression was completely suppressed, suggesting a central effect of FEN to normalize hyperglycemia. Moreover, FEN induced RA-responsive genes in RALDH1 KO mice, demonstrating that FEN can augment RA signaling when RA synthesis is impaired. We show that FEN-mediated beneficial effects are through alterations in retinoid homeostasis genes, and these are strong candidates as therapeutic targets for the treatment of obesity and insulin resistance. Diabetes 62:825–836, 2013

More than one-third of United States adults are obese and at risk for development of type 2 diabetes and a host of other metabolic disorders, including dyslipidemia and cardiovascular disease. Despite the development and clinical use of many antidiabetes drugs, they are limited by adverse effects such as fluid retention, weight gain, congestive heart failure, liver toxicity, and the potential for carcinogenesis (1). Therefore, alternative therapies for the treatment of obesity and type 2 diabetes are needed.

The synthetic retinoid, Fenretinide [N-(4-hydroxyphenyl) retinamide] (FEN) prevents obesity and insulin resistance in mice fed a high-fat (HF) diet (2,3). In addition, FEN lowers serum retinol-binding protein (gene name RBP4) levels in rodents and humans by disrupting the ternary complex of retinol-RBP4-transferrin and thereby by promoting renal clearance of RBP4 (4,5). However, the antiobesity action of FEN appears to be independent of its ability to lower circulating levels of this protein because FEN reduces obesity development in mice lacking RBP4 and does not appear to alter food intake or energy expenditure (3). Currently, FEN is undergoing a phase II trial for treatment of insulin resistance in obese humans with hepatic steatosis (6). Thus, the mechanisms by which FEN can prevent obesity and insulin resistance are of great interest. FEN was originally developed as a chemotherapeutic agent (7), and then was found to attenuate cancer cell growth by mechanisms such as apoptosis and reactive oxygen species generation. However, these effects appear to vary in different cells (8). FEN is now the most widely studied retinoid in clinical trials of breast cancer chemoprevention because of its selective accumulation in breast tissue and its favorable toxicological profile (9,10). One mild and reversible side effect is a reduction in circulating retinol levels and deficits in dark adaptation attributable to lowering of circulating RBP4 levels (4,5,11).

Retinoid homeostasis is tightly regulated by a complex system of enzymes and carriers that can promote the storage of retinol in the form of retinyl esters (RBP4, cellular RBP1, CRBP1, and lecithin:retinol acyltransferase); metabolism to retinoic acid (RA) and signaling through its receptors (retinaldehyde dehydrogenase [RALDH1], cellular RA-binding protein, CRABP, and RA receptors [RARs]); and degradation via cytochrome P450-type enzymes (CYP26A1) (12). It has long been known that RA potently blocks adipogenesis when introduced at early stages of differentiation (13–15). More recently, the importance of retinoid homeostasis in whole-body energy balance and glucose homeostasis has been highlighted in genetic knockout (KO) studies of RALDH1 (lean phenotype), CRBP1, and CRABP1 (obese phenotype) (16–18). Because initial mouse studies indicated that FEN could be a promising therapeutic agent to treat or prevent obesity, and because insulin resistance, glucose intolerance, and human cancer trials have demonstrated few side effects, we sought to further investigate the mechanisms by which FEN inhibits adiposity and alters glucose and lipid homeostasis. We aimed to determine whether FEN inhibits adipocyte differentiation and alters adipose and hepatic gene expression, and whether alterations in retinoid...
homeostasis could contribute to the mechanism of FEN-induced leanness in the setting of diet-induced obesity.

RESULTS

Fenretinide inhibits 3T3-L1 differentiation. Because RA has been shown to inhibit adipocyte differentiation, we examined the effect of FEN on adipocyte differentiation in 3T3-L1 cells. The 1 \( \mu \text{mol/L} \) FEN potently inhibited 3T3-L1 differentiation (Fig. 1A). Similar inhibition was obtained with RA, whereas the peroxisome proliferator–activated receptor (PPAR) \( \gamma \) activator ROSI, a potent inducer of the adipogenic program, was used to stimulate the rate of differentiation. Up to five-fold higher FEN did not affect cell viability (Supplementary Fig. 1). Terminal markers of adipogenesis \( \alpha 2 \), \( CD36 \), adiponectin, and lipoprotein lipase \( LPL \) were almost completely inhibited by FEN or RA (Fig. 1B). \( GLUT4 \) mRNA was highly expressed in differentiated cells but was not detected in undifferentiated control (−VE CONT), RA, or FEN cells (data not shown). Similar results were obtained with the upstream intermediate markers \( PPAR\gamma \) and \( C/EBP\alpha \) (Fig. 1C). Expression of \( C/EBP\beta \) mRNA, which normally increases transiently during early phases of adipogenesis, was not affected by FEN or RA (Fig. 1C).

Because FEN is a synthetic retinoid, we tested its effects on retinoid-signaling genes (Fig. 1D and LE). \( RAR\alpha \) was transiently upregulated with differentiation, and this was prevented by RA only. \( RAR\gamma \) levels were downregulated during differentiation, and this was prevented by RA or FEN and expression levels induced above those of −VE CONT cells. \( RAR\beta \) was not expressed in these cells. RA signaling can be further regulated by several proteins controlling retinoid metabolism that are themselves regulated by RA signaling via RA response elements (RAREs) in their promoters. \( CRBP1 \), \( RALDH1 \), and \( CRABP2 \) all were upregulated with RA or FEN (Fig. 1E). The major degradation enzyme for RA, \( CYP26A1 \), was markedly repressed by induction of differentiation, and this trended to be inhibited by FEN or RA. Strikingly, all the retinoid metabolism genes examined were coordinately repressed with ROSI treatment (Fig. 1D and LE).

Fenretinide inhibits lipid accumulation in fully differentiated 3T3-L1 adipocytes. Next, we tested if FEN could reduce lipid accumulation in fully differentiated 3T3-L1 cells (Fig. 2), because FEN has been shown to inhibit adiposity and adipocyte lipid content in vivo (3). As expected, RA did not affect lipid accumulation in fully differentiated 3T3-L1 cells (15); however, FEN treatment significantly reduced lipid content by 26% (Fig. 2A). The mechanism of this reduction may involve a coordinate reduction in the expression levels of adipocyte genes fatty acid synthase (\( FAS \)), \( LPL \), hormone-sensitive lipase (\( HSL \)), \( ATGL \), leptin, and \( RBP4 \) to levels lower than in vehicle (VEH) and/or RA-treated adipocytes (Fig. 2B and C). FEN significantly induced \( CRBP1 \) and \( RALDH1 \), and it induced small increases in \( RAR\alpha \) and \( RAR\gamma \), but it did not affect the expression of other retinoid genes measured (Fig. 2C). To test whether FEN-treated cells were more insulin-sensitive, cells were stimulated with insulin and Akt/PKB phosphorylation was analyzed. Akt/PKB phosphorylation was increased 3.5-fold in FEN-treated adipocytes, indicating improved insulin sensitivity (Fig. 2D).

Fenretinide improves adipokine levels in mice with HF-induced obesity. Next, we investigated whether FEN treatment would induce similar alterations in vivo. In C57Bl/6 mice, FEN treatment prevented body weight gain over the course of 20 weeks of HF feeding (Fig. 3A), inhibited adiposity (Fig. 3B), and completely normalized
hyperglycemia (Table 1). FEN did not affect lean mass (not shown). White adipose tissue (WAT) dissected from FEN mice and the lipid layer after aqueous buffer homogenization were yellow instead of the normal white or pink (Fig. 3C), suggesting accumulation of FEN (a retinoid with peak UV absorbance at 300–400 nm). Similarly, clinical trials for breast cancer chemoprevention have shown FEN to selectively accumulate in breast, a characteristic fatty tissue (23,24). Thus, we tested whether FEN was acting directly on WAT. As expected, serum leptin levels were reduced (Table 1). Serum RBP4 levels are reduced with FEN treatment (2,5); however, it is not known if FEN affects tissue RBP4 protein levels in vivo. We found that adipose RBP4 protein levels were decreased 40% with FEN compared with HF-fed and chow-fed mice (Table 1). However, hepatic RBP4 protein levels were increased compared with HF-fed mice (Table 1). Elevated levels of serum resistin with HF feeding also were attenuated with FEN treatment (Table 1). Circulating levels and adipose mRNA levels of adiponectin are reduced in obesity and insulin resistance. We found adipose adiponectin mRNA levels were partially normalized, up 63% with FEN treatment (Table 1). Otherwise significance was calculated by ANOVA. Gene expression was analyzed by quantitative PCR analysis. MDI values were removed because no significant differences were observed between MDI = VEH in all cases. Data represents mean ± SEM of three separate experiments (performed on different days and different passage cells). (A high-quality digital representation of this figure is available in the online issue.)
correlating with circulating insulin levels (25,26). We found adipose IR protein levels to be downregulated in HF (Fig. 3D, left panel), inversely correlating with obesity (not shown) and serum insulin levels (Fig. 3D, right panel), and this decrease was attenuated with FEN treatment. Thus, we measured insulin-stimulated lipogenesis in WAT ex vivo as an indicator of WAT insulin sensitivity. Basal lipogenesis in WAT was not altered in HF or FEN HF mice; however, insulin-stimulated lipogenesis was markedly decreased in HF mice and normalized 40% in FEN HF mice (Fig. 3E). Moreover, in mice injected with a bolus of insulin, adipose tissue phosphorylation of Akt/PKB trended to be higher, whereas phosphorylation of p70 S6 kinase substrate S6 and of ERK1/2 were significantly decreased (Fig. 3F). S6 kinase is implicated in negative feedback inhibition of insulin signaling, and mice lacking adipose mTORC1–S6 kinase signaling or whole-body ERK1 are lean. Muscle insulin signaling was unaltered (Supplementary Fig. 2). Together, these findings indicate that improvements in adipose insulin signaling are part of the mechanism by which FEN exerts its beneficial action.

FEN alters adipose and hepatic gene expression. Next, we examined other metabolic genes in WAT that may be altered by HF feeding, obesity, and insulin resistance. We found that PPARγ and C/EBPα were decreased 50% with HF diet, whereas the decrease in FEN was only 25% (Supplementary Fig. 2). HSL and ATGL protein levels were also decreased with HF feeding and increased with FEN treatment (Fig. 3F). Retinoid metabolism gene expression levels were also decreased with HF feeding and increased with FEN treatment (Fig. 3F). RARγ and CRBP1 were decreased with HF feeding and increased with FEN treatment (Fig. 3F). CYP26A1 was increased with ROSI and decreased with FEN treatment (Fig. 3F). These findings suggest that FEN may improve insulin signaling in adipose tissue and restore metabolic gene expression levels.
significantly less (~30%). Similar gene expression changes were observed with IR, aP2, and LPL (Fig. 3G). GLUT4, PEPCK, and resistin were decreased ~80–90% with HF diet, but were three-fold higher with FEN (Fig. 3G). CD36, leptin, and UCP1 mRNA were unaltered with FEN treatment (Fig. 3G and H). Next, we verified whether FEN could alter expression of retinoid metabolism and signaling genes. Adipose RBP4 and RALDH1 mRNA levels were downregulated with HF diet, and this was attenuated with FEN, similar to PPARγ levels (Fig. 3D). Strikingly, FEN treatment strongly induced the CRBP1, RARβ, and CYP26A1 in WAT, above and beyond the levels in chow-fed mice (Fig. 3D). Similar data were obtained from subcutaneous WAT (Fig. 3F). Moreover, we found CRB1, RARβ, and CYP26A1 were similarly upregulated in the liver of FEN mice, whereas RBP4 levels were downregulated
TABLE 1
Serum parameters and tissue levels of metabolically important secreted factors

|                          | Chow       | HF          | FEN-HF      |
|--------------------------|------------|-------------|-------------|
| Serum levels             |            |             |             |
| Glucose (mmol/L)         | 11.9 ± 0.7 | 20.9 ± 0.2† | 11.6 ± 0.6† |
| Insulin (ng/mL)          | 0.7 ± 0.08 | 2.8 ± 0.3†  | 1.6 ± 0.2‡  |
| Leptin (ng/mL)           | 1.3 ± 0.5  | 14.0 ± 1.2† | 9.27 ± 1.0‡ |
| Resistin (ng/mL)         | 2.3 ± 0.4  | 5.0 ± 0.4†  | 3.3 ± 0.5‡  |
| Tumor necrosis factor-α (pg/mL) | 3.5 ± 0.7 | 3.2 ± 0.2  | 3.6 ± 0.4  |
| IL-6 (pg/mL)             | 47.3 ± 15.1| 6.8 ± 1.9   | 16.0 ± 4.2  |
| Tissue levels (fold-change vs. chow) |          |             |             |
| RBP4, adipose protein    | 1.0 ± 0.05 | 1.02 ± 0.08 | 0.62 ± 0.04‡ |
| RBP4, liver protein      | 1.0 ± 0.12 | 0.73 ± 0.06 | 1.07 ± 0.10†|
| Adiponectin, adipose mRNA| 1.0 ± 0.17 | 0.37 ± 0.06†| 0.60 ± 0.04‡|

*P < 0.05; †P < 0.001 for HF or FEN-HF vs. chow; ‡P < 0.05 and ¶P < 0.001 for FEN vs. HF. Serum glucose was measured at 12 weeks of diet treatment and all other factors at 20 weeks, both after 5-h food removal. Data are presented as mean ± SEM with significance tested using one-way ANOVA. For adiponectin, one-way ANOVA was not significant for FEN-HF vs. HF; however, ‡ indicates P = 0.006 with a t test.

(Table 2). We also found that HF-induced elevations in liver triglycerides were substantially decreased with FEN treatment (Table 2). These findings were linked with increased expression of fatty acid transporter CD36 with HF diet that was prevented with FEN (Table 2). Overall, these findings suggest that long-term FEN treatment causes partial normalization of altered metabolic gene expression and potent induction of RA signaling in adipose tissue and liver, despite a reduction in circulating retinol levels. Effect of FEN on energy expenditure, food intake, and hypothalamic gene expression. Despite exhibiting decreased adiposity and serum leptin levels, indirect calorimetry did not show an increase in oxygen consumption as a potential mechanism of FEN action (Fig. 4A and B). Rather, oxygen consumption per mouse increased linearly

TABLE 2
Liver gene expression and triglyceride levels

|                          | Chow       | HF          | FEN-HF      |
|--------------------------|------------|-------------|-------------|
| Liver triglyceride (mg/g tissue) | 15.4 ± 2.0 | 56.5 ± 5.0† | 29.4 ± 5.7# |
| Metabolic genes          |            |             |             |
| 5-h fasted               |            |             |             |
| PPARγ                    | 1.0 ± 0.05 | 0.8 ± 0.08  | 0.6 ± 0.03*#|
| CD36                     | 1.0 ± 0.1  | 2.5 ± 0.26* | 1.3 ± 0.21# |
| LPL                      | 1.0 ± 0.11 | 0.7 ± 0.23  | 1.0 ± 0.30  |
| PPARα                    | 1.0 ± 0.06 | 0.7 ± 0.04* | 0.6 ± 0.05* |
| FAS                      | 1.0 ± 0.13 | 0.8 ± 0.19  | 0.5 ± 0.05* |
| Fed ad libitum           |            |             |             |
| PPARγ                    | 1.0 ± 0.089| 1.2 ± 0.12  | 1.5 ± 0.12* |
| CD36                     | 1.0 ± 0.08 | 2.4 ± 0.40* | 2.2 ± 0.30* |
| LPL                      | 1.0 ± 0.07 | 1.1 ± 0.19  | 1.1 ± 0.13  |
| PPARα                    | 1.0 ± 0.06 | 1.3 ± 0.09  | 1.4 ± 0.11  |
| FAS                      | 1.0 ± 0.12 | 0.4 ± 0.10* | 0.3 ± 0.05* |
| PEPCK                    | 1.0 ± 0.11 | 0.8 ± 0.14  | 0.7 ± 0.09  |
| IR                       | 1.0 ± 0.03 | 0.9 ± 0.05  | 0.9 ± 0.06  |
| Retinoid genes           |            |             |             |
| 5-h fasted               |            |             |             |
| RBP4                     | 1.0 ± 0.05 | 0.9 ± 0.03  | 0.8 ± 0.04* |
| CRBP1                    | 1.0 ± 0.23 | 0.5 ± 0.14  | 2.3 ± 0.53‡ |
| RALDH1                   | 1.0 ± 0.07 | 1.1 ± 0.08  | 0.8 ± 0.03* |
| RARβ                     | 1.0 ± 0.06 | 0.8 ± 0.09  | 2.4 ± 0.25† |
| CYP26A1                   | 1.0 ± 0.14 | 0.5 ± 0.07  | 28.4 ± 1.62†|
| Fed ad libitum           |            |             |             |
| RBP4                     | 1.0 ± 0.04 | 0.9 ± 0.05  | 0.7 ± 0.04† |
| CRBP1                    | 1.0 ± 0.11 | 0.9 ± 0.21  | 2.4 ± 0.28† |
| RALDH1                   | 1.0 ± 0.08 | 1.4 ± 0.16  | 1.1 ± 0.06  |
| RALDH2                   | 1.0 ± 0.13 | 1.0 ± 0.15  | 1.2 ± 0.16  |
| RARα                     | 1.0 ± 0.09 | 1.2 ± 0.04  | 1.3 ± 0.09* |
| RARβ                     | 1.0 ± 0.07 | 0.8 ± 0.06  | 2.5 ± 0.16† |
| CYP26A1                   | 1.0 ± 0.16 | 0.3 ± 0.07  | 12.7 ± 1.43‡|

*P < 0.05; †P < 0.001 for HF or FEN-HF vs. chow; ‡P < 0.05 and ¶P < 0.001 for FEN vs. HF. Data are presented as mean ± SEM with significance tested using one-way ANOVA.
with increased body mass in HF-fed mice (Fig. 4C) and, thus, FEN mice had marginally lower oxygen consumption, appropriate for their weight. Food intake was unaltered with FEN treatment (Fig. 4D). In brown adipose tissue, there was a clear upregulation of CRBP1 and a trend for upregulation of CYP26A1 by FEN; however, UCP1, IR, PEPCK, and RARβ mRNAs were the same in HF and FEN HF mice (Fig. 4E).

Despite not affecting energy expenditure or food intake, we found that FEN completely suppressed hypothalamic NPY gene expression (Fig. 4F). In addition, FEN induced hypothalamic RALDH1, RADLH2, and RARα mRNAs, indicating a central affect of FEN treatment.

**Effect of short-term FEN treatment on adipose and hepatic gene expression.** The large changes in adipose and hepatic gene expression seen in Fig. 3 were associated with long-term FEN treatment (20 weeks), relative leaniness, and major improvements in glucose homeostasis. Next, we tested whether long-term FEN treatment was required for these effects. After 1 week of HF diet or FEN and HF diet, both groups gained ~2 g more than mice fed a chow diet; however, there was a trend for decreased body weight with FEN treatment (Fig. 5A). This effect was not associated with decreased food intake (Fig. 5B).

Strikingly, FEN prevented the HF-induced elevation in serum leptin levels (Fig. 5C), with a similar trend for leptin mRNA in WAT, without an effect on other metabolic genes such as GLUT4, adiponectin, or PEPCK (Fig. 5D). In addition, FEN prevented the HF-induced decrease in CRBP1 mRNA in WAT. Short-term FEN treatment also decreased RBP4 mRNA and induced an increase in RARβ and CYP26A1 in WAT relative to both HF-fed and chow-fed mice (Fig. 5D). HF diet led to a characteristic marked downregulation of hepatic SCD-1 (Fig. 5E) and a 20–30% decrease in adipose GLUT4 (Fig. 5D) mRNA in both HF and FEN HF mice. Hepatic PEPCK, a known target of RA signaling, was induced in liver with short-term FEN. No other differences in metabolic genes were observed in liver with short-term FEN; however, CRBP1, lecithin:retinol acyltransferase (LRAT), RARβ, and CYP26A1 all were markedly induced. In addition, we found that hypothalamic NPY mRNA was reduced 29% and 14% with FEN compared with chow diet or HF diet, respectively (Fig. 5F). Thus, short-term FEN treatment is sufficient to induce RA signaling in adipose tissue, liver, and hypothalamus.

**Gene expression alterations in RALDH1 KO and RBP4 KO mice.** Mice lacking the enzyme RALDH1 are compromised in their ability to make RA (19) and have been shown to be resistant to obesity and insulin resistance (16). We examined whether changes in gene expression induced by FEN treatment in normal mice are similarly altered in mice lacking RALDH1. We confirmed that RALDH1 KO mice are resistant to HF-induced obesity (Fig. 6A). In adipose tissue, key metabolic genes that are downregulated in obesity were approximately two-fold higher in RALDH1 KO mice. Moreover, RBP4, CRBP1, and RARβ were induced 1.5-fold to 3-fold (Fig. 6B). In liver, CRBP1 levels were elevated two-fold; however, CYP26A1 levels were dramatically decreased (Fig. 6C). We hypothesized that CYP26A1 levels were decreased to compensate for the reduction in RA production, and thus we tested whether FEN could induce CYP26A1 mRNA in this setting. RALDH1 KO mice administered FEN and HF diet gained less body mass than mice fed HF diet (Fig. 6D). Strikingly, FEN-induced elevations in CYP26A1 and RARβ in both WAT and liver (Fig. 6E). FEN lowers serum RBP4 protein levels but also prevents obesity in RBP4 KO mice (3). Thus, we tested whether similar gene expression alterations were present in RBP4 KO mice. We found no significant changes in the expression of retinoid metabolism and signaling genes in liver or PG-WAT (Fig. 6F), strongly suggesting RBP4 KO and FEN treatment have largely differing modes of action to improve insulin sensitivity.

**DISCUSSION**

Recent studies have identified important regulators of retinoid homeostasis as potential therapeutic targets for obesity (2,16–18). A major limitation to the use of retinol or retinyl-acetate has been the development of liver disease when these compounds are used in high doses for prolonged periods of time (27). However, FEN shows low toxicity compared with other retinoids (7,9,24). In this article, we show that FEN is a potent modulator of retinoid homeostasis genes in association with an improvement in whole-body physiology and in metabolically important genes.

CRBP1, RARβ, and CYP26A1 are known RA-responsive genes because of the presence of RAREs located in their respective promoter regions. The upregulation of these proteins is thought to simultaneously promote the catabolism of RA and storage of retinol into retinyl-esters, thereby preventing the toxic effects of excess RA signaling mediated via RARs. These markers of RA signaling were found to be upregulated with long-term (20 weeks) or short-term (7 days) FEN treatment in all tissues examined (adipose, liver, and hypothalamus) and 3T3-L1 adipocytes. CYP26A1 and CRBP1 also were upregulated in cancer cells treated with FEN (28). Moreover, FEN-induced elevations in CYP26A1 and RARβ independently of RALDH1 activity in HF-fed mice (Fig. 6E), indicating that increased RA production via RALDH1 is not required. Thus, it appears that FEN is directly or indirectly (or both) acting on RAREs in the promoters of these genes.

Many studies examining the effects of FEN on growth inhibition and apoptosis of cancer cell lines have concluded that FEN and RA exert their cellular effects through different pathways independent of RAR expression (29–31). For example, FEN and 4-MPR (the main catabolite of FEN) were found to bind poorly to recombiant RARs in vitro and only minimally activated RAREs and RXREs in cells (30). However, a role for the RARs has been supported by a number of other investigators. Fanjul et al. (32) demonstrated that 5–20 μmol/L FEN could transactivate RARγ and RARβ. RARβ expression is enhanced in normal human mammary cells after FEN exposure (33), and others have documented that RARβ or RARγ expression enhances FEN-mediated events (34,35). It is not clear why these contrasting results have been reported, but cell-type specific factors such as cofactor expression, epigenetic silencing, or phosphorylation may play a role (36–38).

Clearly, in 3T3-L1 cells, the differentiation process initiates a global downregulation of retinoid-responsive genes that FEN or RA is able to completely inhibit. It has been known that RA potently blocks adipogenesis when introduced at early stages of differentiation (19–15). Our results suggest that FEN acts similarly to RA in 3T3-L1 cells by blocking adipogenesis via inhibition of C/EBPβ-mediated transcription (39).

FEN modestly inhibited lipid accumulation in fully differentiated adipocytes (Fig. 2). These results are in marked
FIG. 4. FEN does not affect energy expenditure or brown adipose UCP1 but completely suppresses hypothalamic NPY. A–C: Energy expenditure of mice during 4–6 weeks on diet during the night (indicated with black bar) and day (A), chow (clear circles), HF (black triangles), or FEN-HF (clear triangles), average over total time measured (B), (chow, clear bar; HF, black bar; or FEN-HF, gray bar), and positive correlation with body weight (C). N = 6–9 mice per dietary group. *P < 0.05 vs. chow by one-way ANOVA and Bonferroni post hoc test; #P < 0.05 by t test FEN-HF vs. HF. D: Gross energy intake during 12–30 days diet (up to energy expenditure measurement). FEN vs. HF is not significant. E and F: Relative gene expression levels in brown adipose tissue (E) and hypothalamus (F), chow (clear bars), HF (black bars), or FEN-HF (gray bars) from mice killed after 20 weeks on diets from 3 months of age. Molecular analysis was performed from 6–8 mice per dietary group. The t test was used to calculate significant difference for brown adipose tissue CYP26A1 HF vs. chow for hypothalamic RALDH1 and RARα FEN-HF vs. HF. Otherwise significance was calculated by ANOVA.
contrast to those obtained with RA treatment (15), indicating that the exact mechanism of FEN action is not identical to that of RA. This may be because unlike RA, FEN leads to a global reduction in vitamin A levels because of the blockade of retinol transport and the renal loss of serum RBP4 in vivo. Short-term FEN treatment was sufficient to cause a downregulation in adipose RBP4 both in C57Bl/6 mice and in RALDH1 KO mice. Importantly, loss of RBP4 alone was not sufficient to induce the gene expression changes seen with either FEN treatment or RALDH1 genetic deletion. Thus, the effects of FEN are not simply attributable to its effects on RBP4 (3).

RA has been shown to inhibit leptin production or secretion (or both) in cells and in rodents (40,41). Paradoxically, RA also induces UCP1 in brown adipose tissue to increase energy expenditure (42–44). FEN inhibited the HF-induced elevation in leptin serum levels and directly inhibited leptin mRNA by 75% in fully differentiated adipocytes. In a clinical trial in overweight women, FEN improved insulin sensitivity and decreased serum leptin levels (45). We did not detect a difference in food intake or an increase in energy expenditure or brown adipose tissue UCP1 levels. However, we found that FEN completely suppressed hypothalamic NPY expression, and a similar decrease has been shown with a neuronal cell line treated with RA (46). This finding provides a specific mechanism for the complete suppression of hepatic glucose production seen during a euglycemic-hyperinsulinemic clamp (3) and complete normalization of HF-induced hyperglycemia seen in our studies and in those of Yang et al. (2), because central administration of NPY can induce hepatic insulin resistance (47).

The importance of retinoid homeostasis in whole-body energy balance and glucose homeostasis has been highlighted in genetic KO studies (16–18). The CRBP1 and CRABP2 findings are consistent with our own because FEN-induced leanness is associated with robust upregulation of these genes in vivo and in 3T3-L1 adipocytes. In our studies, we confirmed that mice lacking RALDH1 are resistant to HF-induced obesity; however, adipose RALDH1 levels were decreased with long-term HF diet and FEN treatment partially prevented this decline. Moreover, embryonic fibroblasts from RALDH1-deficient mice are impaired in their ability to undergo adipogenesis compared with wild-type fibroblasts (16). Reduced PPARγ levels as the mechanism of impaired adipogenesis in RALDH1 KO cells have been implicated (48). However, this phenotype is not consistent with that of the adipose PPARγ KO mice, which are insulin resistant and experience hepatic steatosis with an HF diet (49). We found adipose tissue of RALDH1 KO mice fed an HF diet had higher levels of PPARγ, IR, GLUT4, and adiponectin, consistent with improved whole-body insulin sensitivity and glucose homeostasis. Moreover, inhibition of 3T3-L1 cell adipogenesis by RA or FEN is associated with a marked upregulation of RALDH1.

FEN is the most widely studied retinoid in clinical trials (10) and is currently undergoing phase II clinical trials for treatment of insulin resistance in obese humans with hepatic steatosis (6). There is an urgent need for efficient and
nontoxic drugs to treat obesity and insulin resistance. FEN is relatively nontoxic and has been tested in phase III trials for cancer for periods of up to 5 years. Recently, a novel method to synthesize retinamides has produced a large library of N-(4-hydroxyphenyl)retinamide analogs (50). Although these retinamides have been evaluated for effects on tumor cells and cancer models, it might be useful to screen them for potentially superior effects on the metabolic syndrome. In line with recent studies that have shown that regulators of retinoid homeostasis are potential therapeutic targets for obesity, we present evidence that FEN also is a potent modulator of retinoid homeostasis genes in association with resistance to diet-induced obesity and insulin resistance.

ACKNOWLEDGMENTS
This study was supported by the British Heart Foundation Intermediate Basic Research Fellowship FS/09/026 to N.M., RCUK fellowship to M.D., BBSRC DTG to G.D.M. and C.O., and BBSRC project grant BB/G014272/1 to P.J.M.

No potential conflicts of interest relevant to this article were reported.
N.M. and G.D.M. designed experiments. N.M., G.D.M., P.J.M., M.D., C.O., P.N.S., and K.D.S. performed experiments. N.M. wrote the manuscript and contributed financially to the studies. G.D.M., P.J.M., M.D., C.O., P.N.S., and K.D.S. contributed to discussions. G.D.M. contributed to writing the manuscript. P.J.M. and M.D. reviewed the manuscript.

N.M. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank Gregg Duester (Sanford-Burnham Medical Research Institute, La Jolla, CA) for RADH1 KO mice, Loredana Quadro (Rutgers University, New Brunswick, NJ) for RBP4 KO mice, John Speakman (University of Aberdeen, Aberdeen, UK) for invaluable discussions regarding energy expenditure, Vivian Buchan (Rowett Institute of Nutrition and Health, University of Aberdeen, Aberdeen, UK) for technical contribution with adipokine multiplex analysis, and Tonya Martin (Johnson & Johnson, Aberdeen, UK) for technical contribution with adipokine analysis.


cellular differentiation of C3H10T1/2 and 3T3-L1 adipocytes. J Cell Physiol 2010;225:1279–1287.

E1420

Tozzo E, Desbuquois B. Effects of STZ-induced diabetes and fasting on insulin receptor mRNA expression and insulin receptor gene transcription in rat liver. Diabetes 1992;41:1609–1616.

Muenter MD, Perry HO, Ludvig H. Chronic vitamin A intoxication in adults. Hepatic, neurologic and dermatologic complications. Am J Med 1971;50:129–136.

Villani MG, Appierto V, Cavadieni E, et al. Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1. Clin Cancer Res 2004;10:6265–6275.

Delia D, Aiello A, Lombardi I, et al. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hematopoietic cell lines including those unresponsive to retinoidic acid. Cancer Res 1993;53:6030–6041.

Sherling MS, Shao ZM, Li XS, et al. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis 1995;16:2477–2486.

Fontana JA, Rishi AK. Classical and novel retinoids: their targets in cancer therapy. Leukemia 2002;16:463–472.

Fanjal AN, Delia D, Pierotti MA, Rideout D, Yu Q, Pfahl M. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors [published correction appears in J Biol Chem 1996;271(52):33705]. J Biol Chem 1996;271:22441–22446.

Swischuk L, Ryan K, Lee X, Tsou HC, Peacocke M, Sager R. Down-regulation of retinoic acid receptor beta in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ 1994;5:133–141.

Schilli AH, Henle MT, Boher MA, Birrer MJ. Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst 1998;90:597–605.

Liu G, Wu M, Levi G, Ferrari N. Inhibition of cancer cell growth by all-trans retinoic acid and its analog N-(4-hydroxyphenyl) retinamide: a possible mechanism of action via regulation of retinoid receptors expression. Int J Cancer 1998;78:248–254.

Ren M, Pozzi S, Bustulfit G, Sonnenz G, Rossetti S, Sacchi N. Impaired retinoic acid signal and its analog N-(4-hydroxyphenyl) retinamide: a possible mechanism of action via regulation of retinoid receptors expression. J Natl Cancer Inst 1998;90:597–605.

Liu G, Wu M, Levi G, Ferrari N. Inhibition of cancer cell growth by all-trans retinoic acid and its analog N-(4-hydroxyphenyl) retinamide: a possible mechanism of action via regulation of retinoid receptors expression. Int J Cancer 1998;78:248–254.

Wang A, Alimova IN, Luo P, Jong A, Triche TJ, Wu L. Loss of CAP phosphorylation by RARalpha2 epigenetic silencing and RA resistance. Mol Cell Biol 2005;25:10591–10593.

Bruck N, Vitoux D, Perry C, et al. A coordinated phosphorylation cascade initiated by p38MAPK/MSK1 directs RARalpha to target promoters. EMBO J 2009;28:34–47.

Wang A, Alimova IN, Luo P, Jong A, Triche TJ, Wu L. Loss of CAP phosphorylation by RARalpha mediates transcriptional control of retinoid-induced cancer cell differentiation. FASEB J 2010;24:833–843.

Schwarz EJ, Reginato MJ, Shao D, Krakow SL, Lazar MA. Retinoic acid blocks adipogenesis by inhibiting C/EBPbeta-mediated transcription. Mol Cell Biol 1997;17:1552–1561.

Kumar MV, Scarpace PJ. Differential effects of retinoic acid on uncoupling protein-1 and leptin gene expression. J Endocrinol 1998;157:237–243.

Menendez C, Lave M, Peino R, et al. Retinoic acid and vitamin D3 powerfully inhibit in vitro leptin secretion by human adipose tissue. J Endocrinol 2001;170:425–431.

Alvarez R, Linares J, Yubero P, et al. A novel regulatory pathway of brown fat thermogenesis. Retinoic acid is a transcriptional activator of diabetes.journals.org DIABETES, VOL. 62, MARCH 2013 835

REFERENCES

1. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941–2948.

2. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356–362.

3. Prentier F, Mody N, Graham TE, Peroni OD, Kahn BB. Long-term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosis. Am J Physiol Endocrinol Metab 2009;297:E1420–E1429.

4. Berni R, Formelli F. In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences. FEBS Lett 1992;308:43–45.

5. Formelli F, Carsana R, Costa A, et al. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients. Cancer Res 1989;49:6149–6152.

6. Veterans Medical Research Foundation, University of California, San Diego. A randomized, double-blind study of the effects of fenretinide administered in subjects with obesity. ClinicalTrials.gov identifier: NCT00546455 2008.

7. Moon RC, Thompson HJ, Becci PJ, et al. N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res 1979;39:1329–1346.

8. Hail N Jr, Kim HJ, Lotan R. Mechanisms of fenretinide-induced apoptosis. Apoptosis 2006;11:1677–1694.

9. Rotmensch N, De Palo G, Formelli F, et al. Long-term tolerability of fenretinide on dark adaptation and the ocular surface. J Natl Cancer Inst 1998;18:4633–4644.

10. Bruck N, Vitoux D, Ferry C, et al. A coordinated phosphorylation cascade initiated by p38MAPK/MSK1 directs RARalpha to target promoters. EMBO J 2009;28:34–47.

11. Wang A, Alimova IN, Luo P, Jong A, Triche TJ, Wu L. Loss of CAP phosphorylation by RARalpha mediates transcriptional control of retinoid-induced cancer cell differentiation. FASEB J 2010;24:833–843.

12. Schwarz EJ, Reginato MJ, Shao D, Krakow SL, Lazar MA. Retinoic acid blocks adipogenesis by inhibiting C/EBPbeta-mediated transcription. Mol Cell Biol 1997;17:1552–1561.

13. Kumar MV, Scarpace PJ. Differential effects of retinoic acid on uncoupling protein-1 and leptin gene expression. J Endocrinol 1998;157:237–243.

14. Menendez C, Lave M, Peino R, et al. Retinoic acid and vitamin D3 powerfully inhibit in vitro leptin secretion by human adipose tissue. J Endocrinol 2001;170:425–431.

15. Alvarez R, Linares J, Yubero P, et al. A novel regulatory pathway of brown fat thermogenesis. Retinoic acid is a transcriptional activator of
the mitochondrial uncoupling protein gene. J Biol Chem 1995;270:5666–5673
43. Puigserver P, Vázquez F, Bonet ML, Picó C, Palou A. In vitro and in vivo induction of brown adipocyte uncoupling protein (thermogenin) by retinoic acid. Biochem J 1996;317:827–833
44. Kumar MV, Sunvold GD, Scarpace PJ. Dietary vitamin A supplementation in rats: suppression of leptin and induction of UCP1 mRNA. J Lipid Res 1999;40:824–829
45. Johansson H, Gandini S, Guerrieri-Gonzaga A, et al. Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer. Cancer Res 2008;68:9512–9518
46. Magni P, Beretta E, Scaccianoce E, Motta M. Retinoic acid negatively regulates neuropeptide Y expression in human neuroblastoma cells. Neuropsychopharmacology 2009;39:1628–1636
47. van den Hoek AM, van Heijningen C, Schröder-van der Elst JP, et al. Intracerebroventricular administration of neuropeptide Y induces hepatic insulin resistance via sympathetic innervation. Diabetes 2008;57:2304–2310
48. Reichert B, Yasmeen R, Jeyalakumar SM, et al. Concerted action of aldehyde dehydrogenases influences depot-specific fat formation. Mol Endocrinol 2011;25:799–809
49. He W, Barak Y, Hevener A, et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA 2003;100:15712–15717
50. Mershon SM, Anding AL, Chapman JS, Clagett-Dame M, Stonerock LA, Curley RW Jr. Solid phase-assisted synthesis and screening of a small library of N-(4-hydroxyphenyl)retinamide (4-HPR) analogs. Bioorg Med Chem Lett 2007;17:836–840